Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)

CAPS Rating: 2 out of 5

A biopharmaceutical company focuses on the discovery, development and commercialization of innovative treatments for infectious diseases

Results 1 - 20 of 22 : 1 2 Next »

Recs

0
Member Avatar zojo360 (72.75) Submitted: 3/7/2015 3:01:12 PM : Outperform Start Price: $14.90 ACHN Score: -34.66

From (24/7 Wallstreet)...Achillion Pharmaceuticals Inc. (NASDAQ: ACHN) was started as Underweight at Barclays.

Read more: Top Analyst Upgrades and Downgrades: Alcoa, Apache, Bob Evans, F5 Networks, McDonald’s and More - Alcoa, Inc. (NYSE:AA) - 24/7 Wall St. http://247wallst.com/investing/2015/03/04/top-analyst-upgrades-and-downgrades-alcoa-apache-bob-evans-f5-hain-mcdonalds-and-more/#ixzz3TjRN6pb7
Follow us: @247wallst on Twitter | 247wallst on Facebook

Recs

0
Member Avatar patfactorx (20.09) Submitted: 2/26/2015 12:31:40 PM : Outperform Start Price: $12.47 ACHN Score: -15.84

Hot momentum stock in the Biotech sector. Great way to pick up the strength in the Biotechs.

Recs

0
Member Avatar km00nster (< 20) Submitted: 2/23/2015 10:00:15 PM : Outperform Start Price: $12.63 ACHN Score: -17.01

A takeout target that looks like it's going higher.

Recs

0
Member Avatar TerryFool (77.72) Submitted: 2/13/2015 2:14:28 PM : Outperform Start Price: $9.88 ACHN Score: +2.41

BP 10 TP 20

Recs

0
Member Avatar Jordrok (98.89) Submitted: 2/4/2015 12:12:26 PM : Underperform Start Price: $12.36 ACHN Score: +18.23

No revenues yet.

Recs

1
Member Avatar atlas1701 (73.80) Submitted: 9/30/2014 3:58:09 PM : Outperform Start Price: $10.00 ACHN Score: -2.68

Take out play. ACHN has interesting products and good data, pretty high risk but substantial upside.

Recs

0
Member Avatar DRGRNR (< 20) Submitted: 9/6/2014 5:41:58 PM : Outperform Start Price: $12.06 ACHN Score: -18.15

Healthcare market is looking for competitive HCV products to add price pressure to Gilead's HCV treatment Sovaldi.

Recs

1
Member Avatar rcwcfa (< 20) Submitted: 6/11/2014 8:53:45 PM : Underperform Start Price: $7.25 ACHN Score: -34.44

The company's entire net worth is due to last year's financing. The company will continue to lose cash and financial flexibility unless it gets bought out. Given the performance recently, I expect the stock to drop back down to $4.

Recs

0
Member Avatar genedom (98.47) Submitted: 3/11/2014 11:43:12 PM : Underperform Start Price: $3.15 ACHN Score: -212.12

No future

Recs

3
Member Avatar HarHarMahadev (< 20) Submitted: 2/4/2014 12:02:15 PM : Outperform Start Price: $3.33 ACHN Score: +187.84

Lot of Institutional buying recently..

Recs

1
Member Avatar whoodatstockhot (92.39) Submitted: 9/30/2013 12:50:22 PM : Outperform Start Price: $2.94 ACHN Score: +223.18

One of the best buying opportunites I've seen all year. Stonrg pipeline of hepatitis C medicines in its portfolio.

Recs

1
Member Avatar fatmoneyrz (99.23) Submitted: 9/30/2013 9:47:42 AM : Outperform Start Price: $3.50 ACHN Score: +167.55

This is a best in breed, but volatile one, which should head right back up. Take advantage of the sell offs

Recs

1
Member Avatar TerryHoodSr (79.83) Submitted: 7/31/2013 3:46:45 PM : Outperform Start Price: $6.37 ACHN Score: +37.92

potential

Recs

0
Member Avatar rknapton (< 20) Submitted: 7/23/2013 8:10:16 PM : Underperform Start Price: $7.18 ACHN Score: -20.33

Short. Biopharma. Big insider selling. 6000x P/S . Last 3 years cash flow from selling stock: 44M, 61M, 72M. (Much more than investing activities).

Recs

0
Member Avatar Fishbolb (72.95) Submitted: 10/16/2012 6:42:19 PM : Underperform Start Price: $10.78 ACHN Score: +47.02

Late to the Hep C game.

Recs

1
Member Avatar getrichslowfool (< 20) Submitted: 1/13/2012 3:21:38 PM : Outperform Start Price: $12.32 ACHN Score: -77.28

Yeah it's run up a bunch recently, but I think IDIX will get bought out and this will run up more with it. Time will tell

Recs

1
Member Avatar jamescraigjones (< 20) Submitted: 10/19/2011 10:43:10 AM : Outperform Start Price: $6.22 ACHN Score: -4.13

It is clear to see that the Hep C market will be exploding in the next year to 3 years as developers continue to improve on the technology and pipelines. Regardless of how the sector or the overall market is performing, you cant ignore the kind of money that this market will tap into.

Recs

0
Member Avatar EclecticRecluse (80.41) Submitted: 5/25/2011 10:01:35 AM : Underperform Start Price: $5.87 ACHN Score: -17.44

Low Sales and Return on Equity

Recs

0
Member Avatar THEMATHISNEAR (< 20) Submitted: 2/17/2011 10:24:28 AM : Underperform Start Price: $5.99 ACHN Score: -3.92

Shorting a bunch of biotechs that have run up for no reason. Yes, I expect one to pop, and don't know which one, but I expect that most will fail outright, and the group as a whole will fail to match the S&P.

Recs

0
Member Avatar poorbastard2011 (< 20) Submitted: 1/14/2011 7:04:28 AM : Outperform Start Price: $5.04 ACHN Score: +41.09

Long Term Bullish Breakout
Short Term Upward Sloping Trading Channel
Short Term Bullish Breakout

Results 1 - 20 of 22 : 1 2 Next »

Featured Broker Partners


Advertisement